Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Operating Expenses (2016 - 2025)

Ocular Therapeutix has reported Other Operating Expenses over the past 13 years, most recently at $14.6 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $14.6 million for Q4 2025, up 20.56% from a year ago — trailing twelve months through Dec 2025 was $60.5 million (up 28.13% YoY), and the annual figure for FY2025 was $60.5 million, up 28.13%.
  • Other Operating Expenses for Q4 2025 was $14.6 million at Ocular Therapeutix, down from $14.9 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for OCUL hit a ceiling of $15.7 million in Q2 2025 and a floor of $9.0 million in Q1 2021.
  • Median Other Operating Expenses over the past 5 years was $11.5 million (2024), compared with a mean of $11.9 million.
  • Biggest five-year swings in Other Operating Expenses: surged 56.18% in 2021 and later decreased 7.91% in 2023.
  • Ocular Therapeutix's Other Operating Expenses stood at $10.2 million in 2021, then grew by 12.69% to $11.5 million in 2022, then decreased by 7.91% to $10.6 million in 2023, then rose by 13.54% to $12.1 million in 2024, then increased by 20.56% to $14.6 million in 2025.
  • The last three reported values for Other Operating Expenses were $14.6 million (Q4 2025), $14.9 million (Q3 2025), and $15.7 million (Q2 2025) per Business Quant data.